|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9630
|
|
pubmed:dateCreated |
2008-6-23
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
Axitinib (AG-013736) is a potent and selective oral inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, which have an important role in pancreatic cancer. The aim of this study was to assess the safety and efficacy of gemcitabine plus axitinib versus gemcitabine alone.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
1474-547X
|
|
pubmed:author |
pubmed-author:BajettaEmilioE,
pubmed-author:BaroneCarloC,
pubmed-author:BycottPaulP,
pubmed-author:ChodkiewiczCatherineC,
pubmed-author:KimSinilS,
pubmed-author:LétourneauRichardR,
pubmed-author:LiauKatherineK,
pubmed-author:MaurelJoanJ,
pubmed-author:PithavalaYazdiY,
pubmed-author:RicartAlejandro DAD,
pubmed-author:RixeOlivierO,
pubmed-author:SpanoJean-PhilippeJP,
pubmed-author:TraskPeterP,
pubmed-author:WasanHarpreetH,
pubmed-author:WongRalphR
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
21
|
|
pubmed:volume |
371
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2101-8
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:18514303-Adult,
pubmed-meshheading:18514303-Aged,
pubmed-meshheading:18514303-Aged, 80 and over,
pubmed-meshheading:18514303-Antimetabolites, Antineoplastic,
pubmed-meshheading:18514303-Deoxycytidine,
pubmed-meshheading:18514303-Drug Therapy, Combination,
pubmed-meshheading:18514303-Female,
pubmed-meshheading:18514303-Humans,
pubmed-meshheading:18514303-Imidazoles,
pubmed-meshheading:18514303-Indazoles,
pubmed-meshheading:18514303-Male,
pubmed-meshheading:18514303-Middle Aged,
pubmed-meshheading:18514303-Pancreatic Neoplasms,
pubmed-meshheading:18514303-Proportional Hazards Models,
pubmed-meshheading:18514303-Receptors, Vascular Endothelial Growth Factor,
pubmed-meshheading:18514303-Survival Rate
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study.
|
|
pubmed:affiliation |
Hôpital de la Pitié Salpêtrière, Paris, France. jean-philippe.spano@psl.ap-hop-paris.fr
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
